Paul D. Wes, PhD

Paul Wes is a biotechnology and pharmaceutical executive with over 20 years of experience advancing therapies from discovery to clinical development, specializing in neuroscience. Prior to joining Bexorg, he was site head at Pfizer’s Centers for Therapeutic Innovation (CTI) in New York, leading global teams and driving programs from novel drug targets to clinical candidates. Paul has held senior roles at Lundbeck, Bristol-Myers Squibb, Roche, and Elan Pharmaceuticals, where he established cutting-edge target discovery platforms and fostered industry-academic collaborations. His research on mitochondria, neuroinflammation, and microglial biology has been published in top journals. Paul holds a PhD in Biochemistry, Cellular, and Molecular Biology from Johns Hopkins School of Medicine and conducted postdoctoral research at UCSF with Cori Bargmann. He is also an inventor on patents and a dedicated mentor to the next generation of scientific leaders.